Key Insights

Highlights

Success Rate

81% trial completion

Published Results

204 trials with published results (25%)

Research Maturity

473 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

13.6%

113 terminated out of 828 trials

Success Rate

80.7%

-5.8% vs benchmark

Late-Stage Pipeline

26%

215 trials in Phase 3/4

Results Transparency

43%

204 of 473 completed with results

Key Signals

204 with results81% success113 terminated

Data Visualizations

Phase Distribution

596Total
Not Applicable (135)
Early P 1 (5)
P 1 (85)
P 2 (156)
P 3 (145)
P 4 (70)

Trial Status

Completed473
Terminated113
Unknown81
Recruiting74
Withdrawn43
Active Not Recruiting22

Trial Success Rate

80.7%

Benchmark: 86.6%

Based on 473 completed trials

Clinical Trials (828)

Showing 20 of 20 trials
NCT07619547Not Yet Recruiting

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

NCT07753850Phase 2Not Yet RecruitingPrimary

A Phase 2 Study of SL-325 in Crohn's Disease Patients

NCT05626088Completed

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

NCT04844606Phase 3Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT05509777Phase 3RecruitingPrimary

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT06430801Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT03105102Phase 3Active Not RecruitingPrimary

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT04060303Phase 3Completed

ENhanced Recovery in CHildren Undergoing Surgery

NCT06937099Phase 3RecruitingPrimary

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT07748338CompletedPrimary

Ustekinumab Real World Evidence Study

NCT03167437Phase 1RecruitingPrimary

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT07504510RecruitingPrimary

Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease

NCT06100289Phase 3Recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT03466411Phase 2Active Not RecruitingPrimary

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT06408935Phase 3Active Not RecruitingPrimary

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT03000101Not ApplicableCompletedPrimary

Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease

NCT06663332Phase 3RecruitingPrimary

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT07169123RecruitingPrimary

Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD

NCT07250815Not Yet Recruiting

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT04809363Phase 4Active Not RecruitingPrimary

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Scroll to load more

Research Network

Activity Timeline